...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
【24h】

Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.

机译:胃癌中hSRBC的频繁表观遗传失活及其对应激的p53应答减弱。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

hSRBC is a putative tumor suppressor located at 11p15.4, at which frequent genomic loss has been observed in several human malignancies. To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors. Loss or reduction of hSRBC expression was tumor-specific and correlated with stage and grade of tumors. While allelic loss or somatic mutations of the gene were infrequent, its expression was restored in tumor cells by 5-aza-2'-deoxycytidine treatment and aberrant hypermethylation of 23 CpG sites in the promoter region showed a tight association with altered expression. Transient or stable expression of hSRBC led to a G(1) cell cycle arrest and apoptosis of tumor cells, and strongly suppresses colony forming ability and xenograft tumor growth. In addition, hSRBC elevated apoptotic sensitivity of tumor cells to genotoxic agents, such as 5-FU, etoposide and ultraviolet. Interestingly, hSRBC increased the protein stability of p53 and expression of p53 target genes, such as p21(Waf1), PUMA and NOXA, while hSRBC-mediated cell cycle arrest and apoptosis were abolished by blockade of p53 function. Our findings suggest that hSRBC is a novel tumor suppressor whose epigenetic inactivation contributes to the malignant progression of gastric tumors, in part, through attenuated p53 response to stresses.
机译:hSRBC是一种推定的肿瘤抑制因子,位于11p15.4,在几个人类恶性肿瘤中均观察到频繁的基因组缺失。为了探讨候选hSRBC作为胃癌发生的抑制剂,我们分析了hSRBC在胃组织和细胞系中的表达和突变状态。 hSRBC转录本在所有检查的正常和良性肿瘤组织中均有表达,但在73%(11/15)癌细胞系和41%(46/111)原发性肿瘤中检测不到或非常低。 hSRBC表达的丧失或减少是肿瘤特异性的,并且与肿瘤的阶段和等级相关。虽然该基因的等位基因缺失或体细胞突变很少见,但通过5-氮杂2'-脱氧胞苷处理在肿瘤细胞中恢复了其表达,并且启动子区域中23个CpG位点的异常高甲基化表明其与表达改变紧密相关。 hSRBC的瞬时或稳定表达导致G(1)细胞周期停滞和肿瘤细胞凋亡,并强烈抑制集落形成能力和异种移植肿瘤的生长。另外,hSRBC提高了肿瘤细胞对遗传毒性剂如5-FU,依托泊苷和紫外线的凋亡敏感性。有趣的是,hSRBC增加了p53的蛋白稳定性和p53靶基因(如p21(Waf1),PUMA和NOXA)的表达,而hSRBC介导的细胞周期阻滞和细胞凋亡则由于p53功能的阻断而被消除。我们的发现表明,hSRBC是一种新型的肿瘤抑制因子,其表观遗传失活部分地通过对压力的减弱的p53反应而有助于胃肿瘤的恶性进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号